L-Tyrosine

PreclinicalSmall molecule

DDirection Centrale du Service de Santé des Armées

L-Tyrosine is one of 14 small molecule programs targeting Recovery. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RecoveryCompleted

StressCompleted

RecoveryPreclinical

Completed

StressPreclinical

Completed

Competition

Competitive Landscape

12 competitors in Recovery

#DrugCompanyPhaseTrials

Neurontin

VViatris Specialty LLC

Approved

3 2

Epidiolex

Jazz Pharmaceuticals

Phase 3

1 3

N-Acetyl-L-Cysteine

PPeking University People's Hospital

Phase 2

1 4

BXCL501

BBioXcel Therapeutics Inc

Phase 2

1 5

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 6

Bupivacaine-Fentanyl

SSamuel Lunenfeld Research Institute, Mount Sinai Hospital

Preclinical

1 7

L-Tyrosine

DDirection Centrale du Service de Santé des Armées

Preclinical

1 8

Dual NRT

MMassachusetts General Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Unknown status·HHadassah Medical Organization·Phase 2·NCT02035501·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for L-Tyrosine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L-Tyrosine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L-Tyrosine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Direction Centrale du Service de Santé des Armées company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: DDirection Centrale du Service de Santé des Armées

L-Tyrosine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Stress1 trial

Recovery1 trial

Myopathy1 trial

References

Drug Info

Quick Facts

Related News